Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Cell cycle dependent and independent regulation of AKT activity in germinal center B-cell-like diffuse large B-cell lymphoma – a dual role of cyclin dependent kinase 2

Anezka Rajmonova, Kristyna Kupcova, Jana Senavova, Vaclav Herman, Mariana Pacheco-Blanco, Filip Jura, Tereza Chrbolkova, Nicola Zamboni, Richard Davis, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2025-3259

Published: 2025

Journal Articles

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Blood (2025) 146 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2025-1763

Published: 2025

Journal Articles

Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma

Kristyna Kupcova, Nahum Puebla, Aarthi Goverdhan, Adriana Velasova, Bree Lege, Zahid Rafiq, Victoria Roko, Esha Pisipati, Jingwei Liu, Shao-Qing Kuang, Mien-Chie Hung, Sattva Neelapu, Richard Davis, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 435.

https://doi.org/10.1182/blood-2025-435

Published: 2025

Journal Articles

Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma

Jana Senavova, Tereza Chrbolkova, Eva Pokorna, Anezka Rajmonova, Vaclav Herman, Karin Ravaszova, Kristyna Kupcova, Pavel Klener, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2025-3307

Published: 2025

Journal Articles

Classic Hodgkin lymphoma: the journey over the destination

Ondrej Havranek

Blood (2025) 146 (10): 1152–1153.

https://doi.org/10.1182/blood.2025029621

Published: 2025

Journal Articles

Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Adriana Velasova, Lucie Dlouha, Iva Hamova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Jana Senavova, Katerina Benesova, Petra Svozilkova, Jarmila Heissigerova, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 2979.

https://doi.org/10.1182/blood-2024-211732

Published: 2024

Journal Articles

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Heidi Mocikova, Kristyna Kupcova, Jana Markova, Lubica Gaherova, Maria Maco, Iva Hamova, Adriana Velasova, Alice Sykorova, Pavla Stepankova, Alexandra Kredatusova, Vit Prochazka, Jan Koren, Petr Nehasil, Petra Zemankova, Tomas Kozak, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6193.

https://doi.org/10.1182/blood-2024-210890

Published: 2024

Journal Articles

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Iva Hamova, Prokop Vodicka, Adriana Velasova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Anton Tkachenko, Kamila Polgarova, Jana Salkova, Katerina Benesova, Pavel Klener, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6235.

https://doi.org/10.1182/blood-2024-211263

Published: 2024

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

Role of Autoantigen Induced-B-Cell Receptor Internalization and Its Inhibition for the Biology and Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Patryk Gorniak, Ondrej Havránek, Anna Polak, Przemyslaw Juszczynski

Blood (2023) 142 (Supplement 1): 4141.

https://doi.org/10.1182/blood-2023-187046

Published: 2023

Journal Articles

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Pavel Klener, Jr., Lenka Daumová, Dmitry Kazantsev, Ladislav Anděra, Jiří Petrák, Alexandra Dolníková, Nardjas Bettazová, Petra Kovaříková, Nicol Renešová, Liliana Tušková, Dana Sovilj, Marek Trněný, Magdalena Klanova, Ondrej Havránek

Blood (2023) 142 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2023-182705

Published: 2023

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolníková, Ondrej Havranek, Eva Pokorna, Dmitry Kazantsev, Dana Sovilj, Karel Helman, Magdalena Klanova, Ladislav Andera, Miroslav Strnad, David Chiron, Marek Trneny, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 5996–5997.

https://doi.org/10.1182/blood-2022-168617

Published: 2022

Journal Articles

Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Janneke A. Eken, Marvyn T. Koning, Julieta H. Sepulveda Yanez, Cornelis A.M. van Bergen, Edwin Quinten, Kristyna Kupcova, Ondrej Havranek, Ruben A.L. De Groen, Joost S.P. Vermaat, Daphne de Jong, Philip Kluin, Arjen Cleven, Hassan Jumaa, Hendrik Veelken

Blood (2022) 140 (Supplement 1): 6444–6445.

https://doi.org/10.1182/blood-2022-159420

Published: 2022

Journal Articles

Combinatorial PI3K/AKT Pathway Inhibition As a Therapeutic Approach in Diffuse Large B-Cell Lymphoma

Kristyna Kupcova, Jana Senavova, Vaclav Herman, Tereza Chrbolkova, Iva Ondeckova, Mariana Pacheco-Blanco, Ondrej Havranek

Blood (2022) 140 (Supplement 1): 3149–3150.

https://doi.org/10.1182/blood-2022-166121

Published: 2022

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Ondrej Havranek, Karel Helman, Magdalena Klanova, Miroslav Strnad, Marek Trneny, Pavel Klener, Jr.

Blood (2021) 138 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2021-150517

Published: 2021

Journal Articles

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sykorova, David Belada, Marie Lukasova, Vit K Prochazka, Katarina Hradska, Juraj Ďuraš, Ondrej Havranek, Tomas Kozak

Blood (2021) 138 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2021-148363

Published: 2021

Journal Articles

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-134778

Published: 2020

Journal Articles

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Natalia Baran, PhDMD, Alessia Lodi, PhD, Yogesh Dhungana, PhD, Shannon RENEE Sweeney, PhD, Pandey Renu, PhD, Shelley Herbrich, PhD, Fieke W Hoff, BSc, Anna Skwarska, PhD, Mecit Kaplan, MS, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Marc Warmoes, PhD, Shanti Rojas-Sutterlin, PhD, Andre Haman, PhD, Diogo Troggian Veiga, PhD, Ken Furudate, DDM, PhD, Helen Ma, MS, Karine Harutyunyan, PhD, Wentao Yang, Mihai Gagea, MDPhD, Di Du, PhD, May Daher, Luciana Melo Garcia, MD, Sujan Piya, PhD, Vivian Ruvolo, MS, Sriram Shanmugavelandy, Ningping Feng, PhD, Jason P Gay, MS, Ondrej Havranek, MDPhD, Jared Henderson, MS, Katarzyna Tomczak, PhD, Marcin Kaminski, PhD, Daniel Herranz, PharmD, Adolfo Ferrando, MD, PhD, Elias Jabbour, MD, Maria E Di Francesco, PhD, David T. Teachey, MD, Terzah M. Horton, MD PhD, Katayoun Rezvani, MD PhD, Jun J. Yang, PhD, Steven M. Kornblau, MD, Eric Davis, MD, Koichi Takahashi, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Philip Lorenzi, PhD, Jiyang Yu, PhD, Stefano Tiziani, PhD, Trang Hoang, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-136801

Published: 2020

Journal Articles

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Pavel Klener, Jr., Marek Trněný, Ladislav Andera, MSc, PhD, Zuzana Nahacka, MSc, Magdalena Klanova, MD PhD, Jana Karolova, MD, Michael Svaton, MD, Ondrej Havranek, MDPhD, Jan Soukup, MD, Zuzana Zemanova, PhD, Diana Tuskova, MD, Eva Pokorna, Kristina Forsterova, MSc, PhD, Petra Vockova, MD, Eva Fronkova, MD PhD, Dana Prukova, Ing, PhD

Blood (2018) 132 (Supplement 1): 42.

https://doi.org/10.1182/blood-2018-99-112437

Published: 2018

Journal Articles

Tonic B-cell receptor signaling in diffuse large B-cell lymphoma

Ondrej Havranek, Jingda Xu, Stefan Köhrer, Zhiqiang Wang, Lisa Becker, Justin M. Comer, Jared Henderson, Wencai Ma, John Man Chun Ma, Jason R. Westin, Dipanjan Ghosh, Nicholas Shinners, Luhong Sun, Allen F. Yi, Anusha R. Karri, Jan A. Burger, Tomasz Zal, R. Eric Davis

Blood (2017) 130 (8): 995–1006.

https://doi.org/10.1182/blood-2016-10-747303

Published: 2017

Includes: Multimedia, Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Cell cycle dependent and independent regulation of AKT activity in germinal center B-cell-like diffuse large B-cell lymphoma – a dual role of cyclin dependent kinase 2

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma

Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma

Classic Hodgkin lymphoma: the journey over the destination

Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Role of Autoantigen Induced-B-Cell Receptor Internalization and Its Inhibition for the Biology and Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Cells

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Combinatorial PI3K/AKT Pathway Inhibition As a Therapeutic Approach in Diffuse Large B-Cell Lymphoma

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Tonic B-cell receptor signaling in diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only